This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.Lancet 2017; 389: 1195-205. 10.1016/S0140-6736(16)32616-2CameronDPiccart-GebhartMJGelberRDProcterMGoldhirschAde AzambujaEHerceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialLancet2017389119520510.1016/S0140-6736(16)32616-2Open DOISearch in Google Scholar
Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast 2013; 22: 152-5. 10.1016/j.breast.2013.07.029PintoACAdesFde AzambujaEPiccart-GebhartM.Mrastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapiesBreast201322152510.1016/j.breast.2013.07.029Open DOISearch in Google Scholar
Mathew A, Romond EH. Systemic therapy for HER2-positive early-stage breast cancer. Curr Probl Cancer 2016; 40: 106-16. 10.1016/j.currproblcancer.2016.09.002MathewARomondEH.EHystemic therapy for HER2-positive early-stage breast cancerCurr Probl Cancer2016401061610.1016/j.currproblcancer.2016.09.002Open DOISearch in Google Scholar
Matos E, Zakotnik B, Kuhar CG. Effectiveness of adjuvant trastuzumab in daily clinical practice. Radiol Oncol 2014; 48: 403-7. 10.2478/raon-2013-0081MatosEZakotnikBKuharCG.CGffectiveness of adjuvant trastuzumab in daily clinical practiceRadiol Oncol201448403710.2478/raon-2013-0081Open DOISearch in Google Scholar
Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2768-801. 10.1093/eurheartj/ehw211ZamoranoJLLancellotti P MuñozDRAboyansVAsteggianoRGalderisiM2016ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)Eur Heart J201637276880110.1093/eurheartj/ehw211Open DOISearch in Google Scholar
Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (Baltimore) 2016; 95: e5195. 10.1097/MD.0000000000005195JawaZPerezRMGarlieLSinghMQamarRKhandheriaBKRisk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysisMedicine (Baltimore)201695e519510.1097/MD.0000000000005195Open DOISearch in Google Scholar
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005; 353: 1659-72. 10.1056/NEJMoa052306Piccart-GebhartMJProcterMLeyland-JonesBGoldhirschAUntchMSmithITrastuzumab after adjuvant chemotherapy in HER-2 positive breast cancerN Engl J Med200535316597210.1056/NEJMoa052306Open DOISearch in Google Scholar
Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-65. 10.1016/S1470-2045(05)70251-5DarbySCMcGalePTaylorCWPetoR.Rong-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registriesLancet Oncol200565576510.1016/S1470-2045(05)70251-5Open DOISearch in Google Scholar
Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 2013; 108: 179-82. 10.1038/bjc.2012.575HensonKEMcGalePTaylorCDarbySC.SCadiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancerBr J Cancer20131081798210.1038/bjc.2012.575355354023257897Open DOISearch in Google Scholar
Sardar P, Kundu A, Chatterjee S, Nohria A, Nairooz R, Bangalore S, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer: a systematic review and meta-analysis. Clin Cardiol 2017; 40: 73-81. 10.1002/clc.22631SardarPKunduAChatterjeeSNohriaANairoozRBangaloreSLong-term cardiovascular mortality after radiotherapy for breast cancer: a systematic review and meta-analysisClin Cardiol201740738110.1002/clc.22631649053528244595Open DOISearch in Google Scholar
Jacob J, Belin L, Gobillion A, Daveau-Bergerault C, Dendale R, Beuzeboc P, et al. [Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].[French]. Cancer Radiother 2013; 17: 183-90. 10.1016/j.canrad.2012.12.006JacobJBelinLGobillionADaveau-BergeraultCDendaleRBeuzebocP[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].[French]Cancer Radiother2013171839010.1016/j.canrad.2012.12.00623499212Open DOISearch in Google Scholar
Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-600. 10.1002/cncr.10854KeefeDL.DLrastuzumab-associated cardiotoxicityCancer200295159260010.1002/cncr.1085412237930Open DOISearch in Google Scholar
Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J ClinOncol 2004; 22: 322-9. 10.1200/JC0.2004.01.120PerezEARodehefferR.Rlinical cardiac tolerability of trastuzumabJ Clin. Oncol.200422322910.1200/JC0.2004.01.120Open DOISearch in Google Scholar
Fiuza M. Cardiotoxicity associated with trastuzumab treatmentof HER2+ breast cancer. Adv Ther 2009; 26(Suppl 1): S9-17. 10.1007/s12325-009-0048-zFiuzaM.Mardiotoxicity associated with trastuzumab treatmentof HER2+ breast cancerAdv Ther2009261S91710.1007/s12325-009-0048-z19669637Open DOISearch in Google Scholar
Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Longterm cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107-15. 10.1200/JCO.2005.04.9551GuarneriVLenihanDJValeroVDurandJBBroglioKHessKRLongterm cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experienceJ Clin Oncol20062441071510.1200/JCO.2005.04.955116908934Open DOISearch in Google Scholar
Steel GG. Basic clinical radiobiology. 3rd edition. London: Arnold; 2002. p. 217-39.SteelGG.Basic clinical radiobiology3rdLondonArnold200221739Search in Google Scholar
Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-16. 10.1056/NEJMoa0707064ZetheliusBBerglundLSundströmJIngelssonEBasuSLarssonAUse of multiple biomarkers to improve the prediction of death from cardiovascular causesN Engl J Med200835821071610.1056/NEJMoa070706418480203Open DOISearch in Google Scholar
Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of streching. Endocrinology 1993; 132: 1961-70. 10.1210/endo.132.5.8477647KinnunenPVuolteenahoORuskoahoH.Hechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of strechingEndocrinology199313219617010.1210/endo.132.5.84776478477647Open DOISearch in Google Scholar
Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-51.RaymondIGroenningBAHildebrandtPRNilssonJCBaumannMTrawinskiJThe influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general populationHeart2003897455110.1136/heart.89.7.745176773412807847Search in Google Scholar
Marinko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol Oncol 2014; 48: 105-12. 10.2478/raon-2013-0040MarinkoTDolencJBilban-JakopinC.Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancerRadiol Oncol2014481051210.2478/raon-2013-0040407802824991199Open DOISearch in Google Scholar
Marinko T. Impact of concurrent radiotherapy and treatment with trastuzumab on cardiotoxicity of breast cancer patients. [Dissertation]. Ljubljana: Faculty of Medicine, University of Ljubljana; 2014.MarinkoT.Tmpact of concurrent radiotherapy and treatment with trastuzumab on cardiotoxicity of breast cancer patients[Dissertation]LjubljanaFaculty of Medicine, University of Ljubljana2014Search in Google Scholar
R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013. [cited 2017 Nov 15]. Available at http://www.R-project.org/R Core TeamRA language and environment for statistical computingViennaR Foundation for Statistical Computing2013[cited 2017 Nov 15]Available athttp://www.R-project.org/Search in Google Scholar
Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365-75. 10.1093/jnci/djk064HooningMJBotmaAAlemanBMBaaijensMHBartelinkHKlijnJGLong-term risk of cardiovascular disease in 10-year survivors of breast cancerJ Natl Cancer Inst2007993657510.1093/jnci/djk06417341728Open DOISearch in Google Scholar
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2017. [cited 2017 Nov 7]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfNational Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast CancerVersion 2.2017[cited 2017 Nov 7]Available athttps://www.nccn.org/professionals/physician_gls/pdf/breast.pdfSearch in Google Scholar
Ewer MS, Tan-Chiu E. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well? J Clin Oncol 2007; 25: 5532-3. 10.1200/JCO.2007.14.0657EwerMSTan-ChiuE.Eeversibility of trastuzumab cardiotoxicity: is the concept alive and well?J Clin Oncol2007255532310.1200/JCO.2007.14.0657Open DOISearch in Google Scholar
Giannuzzi P, Temporelli PL, Bosimini E, Silva P, Imparato A, Corrà U, et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 28: 383-90. 10.1016/0735-1097(96)00163-5GiannuzziPTemporelliPLBosiminiESilvaPImparatoACorràUIndependent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunctionJ Am Coll Cardiol1996283839010.1016/0735-1097(96)00163-5Open DOISearch in Google Scholar
Suzuki J, Yanagisawa A, Shigejama T, Tsubota J, Yasumura T, Shimoyama K, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angyology 1999; 50: 37-45. 10.1177/000331979905000105SuzukiJYanagisawaAShigejamaTTsubotaJYasumuraTShimoyamaKEarly detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiographyAngyology199950374510.1177/0003319799050001059924887Open DOISearch in Google Scholar
Hall EJ, Giaccia AJ. Radiobiology for the radiologist. Chapter 20. 7th edition. Philadelphia: Lippincott Williams & Wilkins, Wolters Kluwer; 2012. p 343.HallEJGiacciaAJRadiobiology for the radiologist.207thPhiladelphiaLippincott Williams & Wilkins, Wolters Kluwer2012343Search in Google Scholar
